Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1801–1824 of 2,347 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Intravenous Clear all
Recruiting Early Phase 1 Interventional

Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension

NCT06482853
View directory record Official record
Conditions
Obesity, Hypertension
Interventions
Angiotensin-(1-7), Saline
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 19, 2026, 10:58 PM EDT
Completed Phase 1Phase 2 Interventional

Evaluation of the Safety and Tolerability of Gemini in Subjects With Stage 3-4 Chronic Kidney Disease.

NCT06863467
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
Interventions
Intravenous Gemini, Intravenous placebo
Drug
Lead sponsor
Revelation Biosciences, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
3
States / cities
Chula Vista, California • La Mesa, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 19, 2026, 10:58 PM EDT
Completed Phase 2 Interventional

Omr-IgG-am(Trademark) for Treating Patients With or at High Risk for West Nile Virus Disease

NCT00069316
View directory record Official record
Conditions
West Nile Virus
Interventions
Omr-IgG-am
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 19, 2026, 10:58 PM EDT
Terminated Phase 3 Interventional Results available

Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease

NCT01127633
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Solanezumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years and older
Enrollment
1,457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
64
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 19, 2026, 10:58 PM EDT
Completed Phase 2 Interventional Results available

Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)

NCT01966419
View directory record Official record
Conditions
Acute Episode of Overt Hepatic Encephalopathy, Hepatic Encephalopathy
Interventions
ornithine phenylacetate, placebo intravenous infusion
Drug
Lead sponsor
Ocera Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Coronado, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 19, 2026, 10:58 PM EDT
Completed Phase 4 Interventional Results available

Effects of Intravenous Acetaminophen on Body Temperature and Hemodynamic Responses in Febrile Critically Ill Adults

NCT01869699
View directory record Official record
Conditions
Fever, Critical Illness
Interventions
Acetaminophen, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 19, 2026, 10:58 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19

NCT04315298
View directory record Official record
Conditions
COVID-19
Interventions
Sarilumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,912 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
62
States / cities
Los Angeles, California • Sacramento, California • Santa Monica, California + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Oct 19, 2026, 10:58 PM EDT
Completed Phase 2Phase 3 Interventional

Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure

NCT00520806
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
Relaxin, Placebo
Drug
Lead sponsor
Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies
Industry
Eligibility
18 Years and older
Enrollment
1,161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Chicago, Illinois • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Oct 19, 2026, 10:58 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

Leucine for Depression Study (L-DEP)

NCT03557684
View directory record Official record
Conditions
Depression
Interventions
leucine, PO placebo, lipopolysaccharide (LPS), IV placebo
Dietary Supplement · Other · Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 19, 2026, 10:58 PM EDT
Terminated Phase 2 Interventional Results available

Thiamine as a Metabolic Resuscitator After Cardiac Arrest

NCT03450707
View directory record Official record
Conditions
Cardiac Arrest
Interventions
Thiamine 500 mg IV, Placebo
Drug · Other
Lead sponsor
Michael Donnino
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Oct 19, 2026, 10:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Tolerability Study of Allogeneic Mesenchymal Stem Cell Infusion in Adults With Cystic Fibrosis

NCT02866721
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Mesenchymal Stem Cells
Biological
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 19, 2026, 10:58 PM EDT
Completed Phase 1 Interventional

Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease

NCT04449484
View directory record Official record
Conditions
Parkinson's Disease
Interventions
MEDI1341, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Long Beach, California • Hallandale, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2022 · Synced Oct 19, 2026, 10:58 PM EDT
Completed Phase 2 Interventional

A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease

NCT05291234
View directory record Official record
Conditions
Alzheimer's Disease (AD)
Interventions
ABBV-916, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 90 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
32
States / cities
Tucson, Arizona • Irvine, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 19, 2026, 10:58 PM EDT
Completed Phase 3 Interventional Results available

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3

NCT03102606
View directory record Official record
Conditions
Chemotherapy-induced Neutropenia
Interventions
Plinabulin, Pegfilgrastim, Saline Placebo, D5W Placebo
Drug · Other
Lead sponsor
BeyondSpring Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Stanford, California • Skokie, Illinois • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 19, 2026, 10:58 PM EDT
Completed Phase 2 Interventional Results available

Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"

NCT01030861
View directory record Official record
Conditions
Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Diabetes, High Risk, Impaired Glucose Tolerance
Interventions
Teplizumab, Placebo infusion
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 45 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
17
States / cities
San Francisco, California • Stanford, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 19, 2026, 10:58 PM EDT
Terminated Phase 3 Interventional

Outpatient Treatment With Anti-Coronavirus Immunoglobulin

NCT04910269
View directory record Official record
Conditions
COVID, SARS-CoV2 Infection, Covid19
Interventions
Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Placebo
Biological · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
16
States / cities
Tucson, Arizona • Mather, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 19, 2026, 10:58 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of IV Acetaminophen Versus Oral Acetaminophen

NCT03365622
View directory record Official record
Conditions
Nephrectomy
Interventions
Acetaminophen, Placebos, Placebo Oral Tablet
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 89 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 19, 2026, 10:58 PM EDT
Completed Phase 1Phase 2 Interventional

Zofin (Organicell Flow) for Patients With COVID-19

NCT04384445
View directory record Official record
Conditions
Corona Virus Infection, COVID-19, SARS, Acute Respiratory Distress Syndrome
Interventions
Zofin, Placebo
Biological · Other
Lead sponsor
ZEO ScientifiX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 19, 2026, 10:58 PM EDT
Completed Phase 4 Interventional Results available

Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery

NCT02443402
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 19, 2026, 10:58 PM EDT
Completed Phase 1 Interventional

A Study of the Safety and Pharmacokinetics of PRO283698 in Patients With Rheumatoid Arthritis

NCT00888745
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
placebo, PRO283698
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
9
States / cities
Anniston, Alabama • Orlando, Florida • Ormond Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2010 · Synced Oct 19, 2026, 10:58 PM EDT
Completed Phase 2 Interventional Results available

Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer

NCT01951586
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Denosumab, Zoledronic acid, Placebo to Denosumab, Standard Chemotherapy, Placebo to Zoledronic Acid
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
18
States / cities
Goodyear, Arizona • Anaheim, California • Long Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 19, 2026, 10:58 PM EDT
Completed Phase 1 Interventional

A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study

NCT01230853
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Active Comparator: A, Placebo Comparator B, Active Comparator B, Placebo Comparator A
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Garden Grove, California • San Francisco, California • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 19, 2026, 10:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-Human (FIH) Clinical Study of NM8074 in Healthy Adult Volunteers

NCT05642546
View directory record Official record
Conditions
Healthy
Interventions
NM8074, Placebo
Drug
Lead sponsor
NovelMed Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Oct 19, 2026, 10:58 PM EDT
Terminated Phase 2 Interventional Results available

Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent

NCT04722666
View directory record Official record
Conditions
Major Depressive Disorder With Suicidal Ideation With Intent
Interventions
MIJ821 Intravenous Injection, Placebo Intravenous Injection
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
Birmingham, Alabama • Farmington, Connecticut • Oakland Park, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 19, 2026, 10:58 PM EDT